Komori
Financial results presentation2413M3,Inc.Information and Communications, Services and Others

Earnings Presentation Materials for the Fiscal Year Ending March 2026

In FY2025, revenue, operating profit, profit before tax and net profit increased from the previous year, while the existing businesses also continued to grow steadily. At the same time, the company recognized total impairment losses of ¥6.7 billion, mainly in its overseas businesses, and outlined measures including expanded use of AI, a new mission and shareholder returns including share buybacks.

Worth reading
57In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
10576
¥ million (year-on-year change in operating profit)
Wording
Conditional
How definitive the wording is.

Contents of this document

Financial results presentationFiscal year ended March 2026 (FY2025)13 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥351,363 million+23.0%
Operating profit¥73,547 million+17.0%
Net income¥54,046 million+22.0%
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Medical Platform impairment loss¥2.1 billion
  • Overseas impairment loss¥4.6 billion
  • Gain on sale of shares in associates in the Emerging Businesses GroupApproximately ¥4.0 billion
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
  • AssumptionsNew acquisitions in FY2026
    FiguresNot included
  • AssumptionsUSD exchange rate
    Figures¥150
  • AssumptionsGBP exchange rate
    Figures¥200
  • AssumptionsEUR exchange rate
    Figures¥180
New initiatives
  • Planned implementation of a proprietary AI function that answers physicians' clinical questions
  • Expanded use of AI to optimize and personalize content for individual users
  • Update to the group mission effective 1 June 2026
  • Share buyback of up to ¥20 billion and 20 million shares
  • Addition of video-call functionality to Digi-Sma medical care
Key KPIsA metric the company considers important as a management benchmark.
  • m3.com physician-member total time-spent index124 FY2021Q4=100
    Year on year against the same period last yearUp from 113 in FY2024 Q4
  • Percentage of AI-personalized content on the m3.com homepageMore than 80%
  • Number of physician membersMore than 7 million
  • Number of facilities using Digikaru electronic medical recordsApproximately 9,600
  • Employee coverage of corporate servicesApproximately 7.3 million people
  • Annual number of Digi-Sma medical care consultationsMore than 25 million
    Year on year against the same period last yearApproximately double
  • Digi-Sma medical care rating4.6 Review rating
Unit price and quantity metricsThese figures show sales broken down by price and volume.
  • Number of Digi-Sma medical care users1.8x year on year
  • Digi-Sma medical care payment value1.9x year on year
  • Number of drugs covered by pharmaceutical marketing support servicesApproximately 250 drugs
  • Revenue per drugApproximately ¥150 million
Segment results
Medical Platform
Revenue
¥107,830 million+18.0%
Profit
¥35,918 million+5.0%
Evidence Solutions
Revenue
¥24,521 million+1.0%
Profit
¥5,120 million+18.0%
Career Solutions
Revenue
¥22,799 million+9.0%
Profit
¥5,925 million+5.0%
Site Solutions
Revenue
¥54,353 million+16.0%
Profit
¥5,766 million+6.0%
Patient Solutions
Revenue
¥56,877 million+159.0%
Profit
¥2,686 million+226.0%
Emerging Businesses Group
Revenue
¥2,230 million-9.0%
Profit
¥4,878 million+386.0%
Overseas expansion
Revenue
¥86,921 million+8.0%
Profit
¥14,898 million+1.0%
Medium-term management plan targets
  • Long-term revenue target
    Target valueUp to ¥800 billion
    Target fiscal yearApproximately five years after the end of FY2025
  • Aggregate overseas revenue target
    Target value¥200–250 billion
    Target fiscal yearMedium term
Market Size / Share
  • Member coverage among physicians worldwide50% or higher
  • Cloud-based electronic medical records market shareOverwhelming No. 1
  • Equivalent e-detailing coverage as a percentage of the number of medical representativesEquivalent to more than 38,000 medical representatives, approximately 90% of all medical representatives in Japan
Orders received and order backlog
Order backlog¥37.2 billion (Evidence Solutions)
Year on year against the same period last yearPharmaceutical marketing support order backlog: up 12% year on year
Number of employees
Number of EmployeesApproximately 17,000 people (all group staff across 18 countries)
Annual Dividend
Annual dividend per share¥22
Total dividends¥14.7 billion
Payout ratio
30.3%
Acquisition of treasury shares
Buyback limitUp to ¥20 billion and 20 million shares (3.00% of total shares issued)
Period2 May 2026–30 April 2027
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFiscal year ended March 2026 (FY2025)
Net Sales¥351,363 million (YoY +23.0%)
Operating profit¥73,547 million (YoY +17.0%)
Net income¥54,046 million (YoY +22.0%)
Segment resultsMedical Platform Revenue ¥107,830 million (YoY +18.0%) / Profit ¥35,918 million (YoY +5.0%) / Evidence Solutions Revenue ¥24,521 million (YoY +1.0%) / Profit ¥5,120 million (YoY +18.0%) / Career Solutions Revenue ¥22,799 million (YoY +9.0%) / Profit ¥5,925 million (YoY +5.0%) / Site Solutions Revenue ¥54,353 million (YoY +16.0%) / Profit ¥5,766 million (YoY +6.0%) / Patient Solutions Revenue ¥56,877 million (YoY +159.0%) / Profit ¥2,686 million (YoY +226.0%) / Emerging Businesses Group Revenue ¥2,230 million (YoY -9.0%) / Profit ¥4,878 million (YoY +386.0%) / Overseas expansion Revenue ¥86,921 million (YoY +8.0%) / Profit ¥14,898 million (YoY +1.0%)
Breakdown of Factors Affecting the ChangeFactors Medical Platform impairment loss / Amount ¥2.1 billion, Factors Overseas impairment loss / Amount ¥4.6 billion, Factors Gain on sale of shares in associates in the Emerging Businesses Group / Amount Approximately ¥4.0 billion
Key KPIsIndicator name m3.com physician-member total time-spent index / Value 124 FY2021Q4=100 / Year on year against the same period last year Up from 113 in FY2024 Q4, Indicator name Percentage of AI-personalized content on the m3.com homepage / Value More than 80% / Year on year against the same period last year Not disclosed, Indicator name Number of physician members / Value More than 7 million / Year on year against the same period last year Not disclosed, Indicator name Number of facilities using Digikaru electronic medical records / Value Approximately 9,600 / Year on year against the same period last year Not disclosed, Indicator name Employee coverage of corporate services / Value Approximately 7.3 million people / Year on year against the same period last year Not disclosed, Indicator name Annual number of Digi-Sma medical care consultations / Value More than 25 million / Year on year against the same period last year Approximately double, Indicator name Digi-Sma medical care rating / Value 4.6 Review rating / Year on year against the same period last year Not disclosed
Unit price and quantity metricsIndicator name Number of Digi-Sma medical care users / Value 1.8x year on year, Indicator name Digi-Sma medical care payment value / Value 1.9x year on year, Indicator name Number of drugs covered by pharmaceutical marketing support services / Value Approximately 250 drugs, Indicator name Revenue per drug / Value Approximately ¥150 million
Number of employeesNumber of Employees Approximately 17,000 people (all group staff across 18 countries) / Changes during the period and hiring plan Not disclosed
Assumptions Underlying the Business OutlookAssumptions New acquisitions in FY2026 / Figures Not included, Assumptions USD exchange rate / Figures ¥150, Assumptions GBP exchange rate / Figures ¥200, Assumptions EUR exchange rate / Figures ¥180
Medium-term management plan targetsItem Long-term revenue target / Target value Up to ¥800 billion / Target fiscal year Approximately five years after the end of FY2025, Item Aggregate overseas revenue target / Target value ¥200–250 billion / Target fiscal year Medium term
Annual DividendAnnual dividend per share ¥22 / Interim and Year-End Breakdown Not disclosed / Total dividends ¥14.7 billion
Payout ratio30.3%
Acquisition of treasury sharesBuyback limit Up to ¥20 billion and 20 million shares (3.00% of total shares issued) / Period 2 May 2026–30 April 2027
Orders received and order backlogOrder backlog ¥37.2 billion (Evidence Solutions) / Year on year against the same period last year Pharmaceutical marketing support order backlog: up 12% year on year
Market Size / ShareItem Member coverage among physicians worldwide / Value 50% or higher, Item Cloud-based electronic medical records market share / Value Overwhelming No. 1, Item Equivalent e-detailing coverage as a percentage of the number of medical representatives / Value Equivalent to more than 38,000 medical representatives, approximately 90% of all medical representatives in Japan
New initiativesPlanned implementation of a proprietary AI function that answers physicians' clinical questions, Expanded use of AI to optimize and personalize content for individual users, Update to the group mission effective 1 June 2026, Share buyback of up to ¥20 billion and 20 million shares, Addition of video-call functionality to Digi-Sma medical care
Items this document does not state (13)
Ordinary incomeGross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsRisk amount incorporated into the outlookFinancial targetsCapital expendituresKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The existing businesses performed steadily, while revenue and profit grew, led by the overseas businesses. By segment, contributions came from the acquisition of Patient Solutions, gains on the sale of shares in associates in the Emerging Businesses Group, and growth in Europe and APAC within the overseas businesses. The company explained that the impairment losses were mainly attributable to changes in healthcare policy and the external environment, including revisions to medical service fees, doctors' strikes and changes in healthcare policy in the UK, and changes in vaccine-related policy in the US.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Earnings Presentation Materials for the Fiscal Year Ending March 2026 | M3,Inc. (2413) timely disclosure | Komori